In a filing, Boston Scientific Corp revealed its EVP & Group Pres, Cardiology Fitzgerald Joseph Michael unloaded Company’s shares for reported $5.23 million on Aug 01 ’25. In the deal valued at $104.63 per share,50,000 shares were sold. As a result of this transaction, Fitzgerald Joseph Michael now holds 178,342 shares worth roughly $18.39 million.
Then, Butcher Arthur C sold 17,313 shares, generating $1,811,520 in total proceeds. Upon selling the shares at $104.63, the EVP& Grp Pres, MedSurg & APAC now owns 23,600 shares.
Before that, ARTHUR C BUTCHER bought 17,313 shares. Boston Scientific Corp shares valued at $1,811,519 were divested by the Officer at a price of $104.63 per share.
Leerink Partners initiated its Boston Scientific Corp [BSX] rating to an Outperform in a research note published on June 16, 2025; the price target was $118. A number of analysts have revised their coverage, including Needham’s analysts, who increased its forecast for the stock in mid April from “a Hold” to “a Buy”. Deutsche Bank also remained covering BSX and has increased its forecast on January 10, 2025 with a “Buy” recommendation from previously “Hold” rating. Needham revised its rating on October 18, 2024. It rated BSX as “a Hold” which previously was an “a Buy”.
Price Performance Review of BSX
On Friday, Boston Scientific Corp [NYSE:BSX] saw its stock jump 0.17% to $103.14. Over the last five days, the stock has lost -2.15%. Boston Scientific Corp shares have risen nearly 39.83% since the year began. Nevertheless, the stocks have risen 15.47% over the past one year.
How much short interest is there in Boston Scientific Corp?
A steep rise in short interest was recorded in Boston Scientific Corp stocks on 2025-07-15, growing by 2.08 million shares to a total of 19.57 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 17.49 million shares. There was a rise of 10.61%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 30, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $90 price target.
